Premium
Dermal elastolysis in the setting of combination immunotherapy
Author(s) -
Dickinson Kirsten E.,
Price Lulit,
Wanat Karolyn A.,
Swick Brian L.
Publication year - 2019
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/cup.13492
Subject(s) - nivolumab , medicine , immunotherapy , chemotherapy , programmed cell death 1 , pathology , dermatology , oncology , cancer , pd l1
Multiple cutaneous side effects have been reported with the use of immunotherapies including programmed cell death protein 1 inhibitors. We report 2 patients who presented with papillary dermal elastolysis presenting as multiple, skin‐colored, wrinkled papules and atrophic macules following an inflammatory eruption in the setting of combination chemotherapy with nivolumab and cabiralizumab. These two cases highlight a novel finding, elastolysis in the setting of chemotherapy with nivolumab and cabiralizumab.